Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420
Frank S. Lieberman, Meihua Wang, H. Ian Robins, Christina I. Tsien, Walter J. Curran, Maria Werner-Wasik, Ryan P. Smith, Christopher Schultz, Alan C. Hartford, Peixin Zhang, Minesh P. Mehta
Dive into the research topics of 'Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420'. Together they form a unique fingerprint.